CoverageForm 410-K10-Q8-K13D13G13F

MBRX Moleculin Biotech, Inc. - 8-K

Filed May 26, 2026. See issuer overview · financials · original on SEC.gov ↗
Accession
0001437749-26-018317
7.019.01

Item 7.01 - Regulation FD Disclosure

107 words

Item 7.01

Regulation FD Disclosure

On May 26, 2026, Moleculin Biotech, Inc. (the “Company”) is using the attached presentation for its corporate presentation posted on the Company’s website and is set forth as Exhibit 99.1 herein.

The information contained in Item 7.01 of this Current Report on Form 8-K, including Exhibit 99.1, is being furnished and shall not be “filed” for the purpose of the Securities Exchange Act of 1934, as amended (“Exchange Act”), nor shall it be incorporated by reference in any filing under the Exchange Act or the Securities Act of 1933, as amended (“Securities Act”), unless specifically identified therein as being incorporated by reference.

Item 9.01 - Financial Statements and Exhibits

28 words

Item 9.01

Financial Statements and Exhibits.

(d)

Exhibits.

Exhibit No.

Description

99.1

Investor Presentation dated May 2026

104

Cover page Interactive Data File (formatted as Inline XBRL document)